Treatment guidelines for chronic inflammatory demyelinating polyneuropathy (CIDP), an autoimmune neuro-muscular condition impacting the myelin that insulates and protects peripheral nerves causing mobility and sensory impairment, have been in place for many years with new treatment approvals being scarce. Newly approved treatments including Fc-antibody fragment treatments offer potentially safer, more efficacious treatments that could change practice guidelines and improve patient outcomes and satisfy previously unmet needs. Education on historical treatment approaches for CIDP, the burden of disease, the pathophysiology of CIDP and diagnostic challenges, and the emerging biologic treatments is needed for the multidisciplinary healthcare team treating patients with CIDP to improve patient outcomes and raise the standard of care.
In this CME Outfitters Snack, expert faculty will address the impact of CIDP and common challenges the multidisciplinary healthcare team faces, including disease burden and pathophysiology, guideline best practices for diagnosis and treatment, and emerging biologic treatments.
At the conclusion of this activity, learners will be able to better:
Supported through an independent educational grant from argenx.
Neurologists, neuroimmunologists, physician associates (PAs), nurse practitioners (NPs) and pharmacists in the neurology or neuroimmunology setting
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.00 contact hours (0.1 CEUs) of continuing pharmacy credit (JA0007185-0000-24-075-H01-P).
This activity is designated for 1.00 contact hours.
California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 11/06/2025. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Dr. Lewis reports the following financial relationships:
Advisory Board and Consultant: Annexon, Inc.; argenx; BioCryst Pharmaceuticals, Inc.; CSL Behring; Dianthus Therapeutics; Grifols; Immunovant, Inc.; Johnson & Johnson, Inc.; Nervosave Therapeutics; Nuvig Therapeutics, Inc.; Sanofi; Seismic; and Takeda Pharmaceutical Company Limited
Other financial or material support: Boehringer Ingleheim (DSMB); Medscape and UpToDate, Inc. (Royalties)
Ms. Ross reports the following financial relationships:
Consultant: Alexion. Pharmaceuticals, Inc.; Amgen Inc.; argenx; Bristol Myers Squibb; EMD Serono; Roche; Sandoz; TG Therapeutics, Inc.; and UCB, Inc.
Ms. Sheil reports no financial relationships to disclose.
Dr. Suresh reports no financial relationships to disclose.
The following individuals have no financial relationships to disclose:
Jeffrey Helfand, DO (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
Mary Gleason, PhD, CHCP (Planning Committee)
John Jones, PharmD (Planning Committee)
David Modrak, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Call us at 877.CME.PROS (877.263.7767).
SN-247-110624-43
